治療癌癥如果不把癌癥干細(xì)胞徹底清除,，癌癥很容易復(fù)發(fā)和轉(zhuǎn)移。日本京都大學(xué)的研究人員日前表示,，他們找到了癌癥干細(xì)胞含有的一種標(biāo)志蛋白,，有望對癌細(xì)胞做到“斬草除根”,。
京都大學(xué)消化內(nèi)科教授千葉勉領(lǐng)導(dǎo)的研究小組在研究中注意到消化道中的一種蛋白質(zhì)Dclk1，他們分析了罹患大腸癌的實驗鼠,，發(fā)現(xiàn)含這種蛋白質(zhì)的細(xì)胞會在較長一段時間內(nèi)持續(xù)產(chǎn)生癌細(xì)胞,。
該研究小組通過基因操作成功并有選擇地清除了含Dclk1蛋白質(zhì)的細(xì)胞，實驗鼠體內(nèi)的大腸癌組織面積縮小了80％以上,，有些甚至完全消失,，而且未發(fā)現(xiàn)副作用。
治療癌癥如果不把癌癥干細(xì)胞徹底清除,，則癌癥很容易復(fù)發(fā)和轉(zhuǎn)移,，因此必須找到癌癥干細(xì)胞，對其“斬草除根”,。
而此前人們陸續(xù)發(fā)現(xiàn)的癌癥干細(xì)胞所含的一些標(biāo)志物質(zhì)同時也存在于正常干細(xì)胞內(nèi),，如果以這些物質(zhì)為目標(biāo)清除癌癥干細(xì)胞的話，會誤傷到正常干細(xì)胞,，導(dǎo)致副作用的出現(xiàn),。(生物谷Bioon.com)
doi:10.1038/ng.2481
PMC:
PMID:
Dclk1 distinguishes between tumor and normal stem cells in the intestine
Yuki Nakanishi, Hiroshi Seno, Ayumi Fukuoka, Taro Ueo, Yuichi Yamaga, Takahisa Maruno,Naoko Nakanishi, Keitaro Kanda, Hideyuki Komekado, Mayumi Kawada, Akihiro Isomura,Kenji Kawada, Yoshiharu Sakai, Motoko Yanagita, Ryoichiro Kageyama, Yoshiya Kawaguchi, Makoto M Taketo, Shin Yonehara & Tsutomu Chiba
There is great interest in tumor stem cells (TSCs) as potential therapeutic targets; however, cancer therapies targeting TSCs are limited. A drawback is that TSC markers are often shared by normal stem cells (NSCs)1, 2, 3, 4; thus, therapies that target these markers may cause severe injury to normal tissues. To identify a potential TSC-specific marker, we focused on doublecortin-like kinase 1 (Dclk1). Dclk1 was reported as a candidate NSC marker in the gut5, 6, but recent reports have implicated it as a marker of differentiated cells (for example, Tuft cells)7, 8. Using lineage-tracing experiments, we show here that Dclk1 does not mark NSCs in the intestine but instead marks TSCs that continuously produce tumor progeny in the polyps of ApcMin/+ mice. Specific ablation of Dclk1-positive TSCs resulted in a marked regression of polyps without apparent damage to the normal intestine. Our data suggest the potential for developing a therapy for colorectal cancer based on targeting Dclk1-positive TSCs.
